Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 5/20 | 0.35 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.35 |
| ▸ | PLK4 | O00444 | 1/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.35 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.35 |
| ▸ | MET | P08581 | 1/20 | 0.35 |
| ▸ | ROS1 | P08922 | 1/20 | 0.35 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.35 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.35 |
| ▸ | AXL | P30530 | 1/20 | 0.35 |
| ▸ | FLT4 | P35916 | 1/20 | 0.35 |
| ▸ | FLT3 | P36888 | 1/20 | 0.35 |
| ▸ | FRK | P42685 | 1/20 | 0.35 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.35 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.35 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.35 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.35 |
| ▸ | HIPK4 | Q8NE63 | 1/20 | 0.35 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30598890 | 1.00 | GRM2 (0.35) | GRM2KDRROCK1PLK4ROCK2 | |
| SCHEMBL30598973 | 0.86 | HTR2A (0.38) | GRM2KDRROCK1PLK4ROCK2 | |
| SCHEMBL25186469 | 0.86 | HTR2A (0.38) | GRM2KDRROCK1PLK4ROCK2 | |
| SCHEMBL30004086 | 0.80 | GRM2 (0.42) | GRM2KDRROCK1NTRK1FLT3 | |
| SCHEMBL27086356 | 0.80 | GRM2 (0.42) | GRM2KDRROCK1NTRK1FLT3 | |
| SCHEMBL32686271 | 0.78 | GRM2 (0.33) | GRM2ROCK1PIM1CSNK1A1CDK5 | |
| SCHEMBL21200262 | 0.78 | ROCK1 (0.41) | GRM2KDRROCK1PLK4ROCK2 | |
| SCHEMBL30825344 | 0.78 | PIK3CD (0.44) | GRM2KDRROCK1PLK4ROCK2 | |
| SCHEMBL29089859 | 0.78 | GRM2 (0.37) | GRM2KDRROCK1PLK4ROCK2 | |
| SCHEMBL29514638 | 0.78 | ROCK1 (0.41) | GRM2KDRROCK1PLK4ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4709718-A1 | 6-SUBSTITUTED-3-PHENYL-ISOINDOLIN-1-ONES AS CBL-B INHIBITORS SELECTIVE OVER C-CBL | Genentech Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| US-20250304563-A1 | ACTIVATORS OF EFFECTOR T CELLS | ORUM THERAPEUTICS, INC. (KR) | 2025-10-02 | — | — | US | disclosed |
| EP-4602028-A1 | CBL-B MODULATORS AND USES THEREOF | Nimbus Clio, Inc. (US) | 2025-08-20 | — | — | EP | disclosed |
| EP-4490152-A1 | ACTIVATORS OF EFFECTOR T CELLS | Orum Therapeutics Inc. (KR) | 2025-01-15 | — | — | EP | disclosed |
| US-12187709-B2 | Lactams as CBL-B inhibitors selective over C-CBL | GENENTECH, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| EP-4426691-A1 | LACTAMS AS CBL-B INHIBITORS SELECTIVE OVER C-CBL | Genentech, Inc. (US) | 2024-09-11 | — | — | EP | disclosed |
| WO-2024081311-A1 | CBL-B MODULATORS AND USES THEREOF | NIMBUS CLIO, INC. (US) | 2024-04-18 | — | — | WO | disclosed |
| WO-2024081311-A1 | CBL-B MODULATORS AND USES THEREOF | NIMBUS CLIO, INC. (US) | 2024-04-18 | — | — | WO | disclosed |
| WO-2023170608-A1 | ACTIVATORS OF EFFECTOR T CELLS | ORUM THERAPEUTICS, INC. (KR) | 2023-09-14 | — | — | WO | disclosed |
| WO-2023170608-A1 | ACTIVATORS OF EFFECTOR T CELLS | ORUM THERAPEUTICS, INC. (KR) | 2023-09-14 | — | — | WO | disclosed |
| US-20230212153-A1 | LACTAMS AS CBL-B INHIBITORS SELECTIVE OVER C-CBL | GENENTECH, INC. (US) | 2023-07-06 | — | — | US | disclosed |
| WO-2023081853-A1 | LACTAMS AS CBL-B INHIBITORS SELECTIVE OVER C-CBL | GENENTECH, INC. (US) | 2023-05-11 | — | — | WO | disclosed |
| US-20220324835-A1 | INHIBITORS OF CBL-B AND METHODS OF USE THEREOF | NURIX THERAPEUTICS, INC. | 2022-10-13 | — | — | US | disclosed |
| EP-3743063-A1 | INHIBITORS OF CBL-B AND METHODS OF USE THEREOF | Nurix Therapeutics, Inc. (US) | 2020-12-02 | — | — | EP | disclosed |
| WO-2019148005-A1 | INHIBITORS OF CBL-B AND METHODS OF USE THEREOF | NURIX THERAPEUTICS, INC. (US) | 2019-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304563-A1 | ACTIVATORS OF EFFECTOR T CELLS | CBLB, CBL, CBLC | GRM2 4213/4885KDR 2291/4885ROCK1 1193/4885 |
| US-20230212153-A1 | LACTAMS AS CBL-B INHIBITORS SELECTIVE OVER C-CBL | CBL, CBLB, CBLC | GRM2 4580/4885KDR 1492/4885ROCK1 1600/4885 |
| US-12187709-B2 | Lactams as CBL-B inhibitors selective over C-CBL | CBL, CBLB, CBLC | GRM2 4580/4885KDR 1492/4885ROCK1 1600/4885 |
| US-20220324835-A1 | INHIBITORS OF CBL-B AND METHODS OF USE THEREOF | CBLB, CBL, CBLC | GRM2 4100/4885KDR 3422/4885ROCK1 2447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.